Balyasny Asset Management’s LumiraDx Limited Warrant LMDXW Stock Holding History

Balyasny Asset Management’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-184,280	Closed	-$1.38K	–	3262
2023 Q4	$1.38K	Hold	184,280	–	–	﹤0.01%	2427
2023 Q3	$6.65K	Sell	184,280 -42,214	-19%	-$1.58K	﹤0.01%	2187
2023 Q2	$6.78K	Sell	226,494 -19,573	-8%	-$1.08K	﹤0.01%	2191
2023 Q1	$20.9K	Hold	246,067	–	–	﹤0.01%	2439
2022 Q4	$14.5K	Buy	246,067 +115,025	+88%	+$15.7K	﹤0.01%	2521
2022 Q3	$14K	Hold	131,042	–	–	﹤0.01%	2614
2022 Q2	$118K	Buy	+131,042	New	+$113K	﹤0.01%	2265

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Balyasny Asset Management's LMDXW Position: Q1 2024 in Review

Balyasny Asset Management sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2024, closing a stake of 184,280 shares — an estimated $1.38K sold.

Balyasny Asset Management first reported a position in LMDXW in Q2 2022 and held it in 7 quarters. The position peaked at $118K in Q2 2022. 4 funds tracked by Wall St. Rank hold LMDXW as of Q1 2024.

Balyasny Asset Management reported no remaining LumiraDx Limited Warrant position as of Q1 2024 after selling out during the quarter.
Balyasny Asset Management sold 184,280 LumiraDx Limited Warrant shares in Q1 2024, an estimated $1.38K.
Balyasny Asset Management first reported a position in LumiraDx Limited Warrant in Q2 2022 and held it in 7 quarters.
Balyasny Asset Management's LumiraDx Limited Warrant position peaked at $118K in Q2 2022.
4 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.